Mercurio Valentina, Cuomo Alessandra, Naranjo Mario, Hassoun Paul M
Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Department of Translational Medical Sciences, Federico II University, Naples, Italy.
Compr Physiol. 2021 Apr 1;11(2):1805-1829. doi: 10.1002/cphy.c200025.
Inflammatory processes are increasingly recognized in the pathogenesis of the vascular remodeling that characterizes pulmonary arterial hypertension (PAH). Chronic inflammation may contribute to disease progression or serve as a biomarker of PAH severity. Furthermore, inflammatory pathways may represent possible therapeutic targets for novel PAH-specific drugs beyond the currently approved therapies targeting the endothelin, nitric oxide/cyclic GMP, and prostacyclin biological pathways. The main focus of this article is to provide recent advances in the understanding of the role of inflammatory pathways in the pathogenesis of PAH from preclinical studies and current clinical data supporting chronic inflammation in PAH patients and to discuss emerging therapeutic implications. © 2021 American Physiological Society. Compr Physiol 11:1805-1829, 2021.
炎症过程在肺动脉高压（PAH）所特有的血管重塑发病机制中越来越受到认可。慢性炎症可能促进疾病进展或作为PAH严重程度的生物标志物。此外，炎症途径可能代表了新型PAH特异性药物的潜在治疗靶点，这些药物超越了目前已批准的针对内皮素、一氧化氮/环磷酸鸟苷和前列环素生物途径的疗法。本文的主要重点是从临床前研究以及支持PAH患者慢性炎症的当前临床数据中，阐述炎症途径在PAH发病机制中作用的最新进展，并讨论新出现的治疗意义。© 2021美国生理学会。综合生理学11:1805 - 1829, 2021。
